High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival

被引:54
作者
Laupeze, B
Amiot, L
Drenou, B
Bernard, M
Branger, B
Grosset, JM
Lamy, T
Fauchet, R
Fardel, O
机构
[1] Fac Pharm, INSERM, U456, F-35043 Rennes, France
[2] Fac Med, Lab Univ Hematol & Biol Cellules Sanguines, Rennes, France
[3] Hop Pontchaillou, Serv Hematol Clin, Rennes, France
[4] Fac Med, Dept Sante Publ, Rennes, France
关键词
acute myeloid leukaemia (AML); multidrug resistance protein (MRP); dye efflux; treatment outcome;
D O I
10.1046/j.0007-1048.2002.03350.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multidrug resistance protein (MRP) activity was investigated in 44 newly diagnosed acute myeloid leukaemia (AML) patients using a functional assay based on efflux of carboxy-2',7'-dichlorofluorescein, an anionic dye handled by both MRP1 and MRP2. Elevated MRP transport was detected in 29% of cases. but was not significantly correlated with sex, age. white blood cell count at diagnosis or karyotype. In contrast, it was associated with secondary AML (P = 0.002), CD34 positivity (P = 0.041) and P-glycoprotein activity (P = 0.01). There was a lower rate of complete remission in MRP-positive patients versus MRP-negative patients (23% versus 81%: P = 0.001): overall survival was also better for MRP-negative patients (P = 0.004). These data indicate a probable role for MRP activity in the clinical outcome of AML.
引用
收藏
页码:834 / 838
页数:5
相关论文
共 11 条
[1]   Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival [J].
Borg, AG ;
Burgess, R ;
Green, LM ;
Scheper, RJ ;
Yin, JAL .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (04) :1083-1091
[2]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[3]  
Filipits M, 1997, CLIN CANCER RES, V3, P1419
[4]   Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood [J].
Laupèze, B ;
Amiot, L ;
Payen, L ;
Drénou, B ;
Grosset, JM ;
Lehne, G ;
Fauchet, R ;
Fardel, O .
LIFE SCIENCES, 2001, 68 (11) :1323-1331
[5]   Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients [J].
Legrand, O ;
Simonin, G ;
Perrot, JY ;
Zittoun, R ;
Marie, JP .
BLOOD, 1998, 91 (12) :4480-4488
[6]  
Leith CP, 1999, BLOOD, V94, P1086
[7]   Multidrug resistance in acute leukemia: A comparison of different diagnostic methods [J].
Pall, G ;
Spitaler, M ;
Hofmann, J ;
Thaler, J ;
Ludescher, C .
LEUKEMIA, 1997, 11 (07) :1067-1072
[8]   Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes [J].
Payen, L ;
Courtois, A ;
Campion, JP ;
Guillouzo, A ;
Fardel, O .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (12) :1967-1975
[9]   Expression of breast cancer resistance protein in blast cells from patients with acute leukemia [J].
Ross, DD ;
Karp, JE ;
Chen, TT ;
Doyle, LA .
BLOOD, 2000, 96 (01) :365-368
[10]   Novel mechanisms of drug resistance in leukemia [J].
Ross, DD .
LEUKEMIA, 2000, 14 (03) :467-473